AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by research analysts at Bryan, Garnier & Co in a research note issued to investors on Friday.

Several other analysts also recently issued reports on the stock. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, September 7th. Barclays set a GBX 6,300 ($84.79) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a report on Wednesday, September 13th. Goldman Sachs Group reaffirmed a “sell” rating and set a GBX 3,800 ($51.14) price objective on shares of AstraZeneca in a report on Tuesday, October 17th. Liberum Capital reaffirmed a “buy” rating and set a GBX 4,800 ($64.60) price objective on shares of AstraZeneca in a report on Tuesday, September 5th. Finally, Natixis raised shares of AstraZeneca from a “neutral” rating to a “buy” rating and upped their price objective for the stock from GBX 5,000 ($67.29) to GBX 5,738 ($77.23) in a report on Wednesday, September 6th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of GBX 5,169 ($69.57).

Shares of AstraZeneca (LON:AZN) opened at GBX 4,866.50 ($65.50) on Friday. AstraZeneca has a 1 year low of GBX 4,136.50 ($55.67) and a 1 year high of GBX 5,520 ($74.29).

WARNING: “AstraZeneca (AZN) Given “Buy” Rating at Bryan, Garnier & Co” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/astrazeneca-azn-given-buy-rating-at-bryan-garnier-co/1764961.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.